09:29 AM EST, 01/21/2025 (MT Newswires) -- InMed Pharmaceuticals ( INM ) said Tuesday that its INM-901 small molecule drug candidate for Alzheimer's disease reduced several plasma and brain markers of neuroinflammation in the trial.

The company said the study showed that INM-901 treated groups demonstrated a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines and neurofilament light chain in the plasma for the high-dose treated group.

InMed also said the trial demonstrated a reduction of several key neuroinflammatory genes in the brain.

Shares of the company were up 43% in recent Tuesday premarket activity.